Trial Profile
Randomized Study for the Assessment of Nitazoxanide in the Treatment of Chronic Hepatitis C Genotype 4.
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 28 Nov 2015
Price :
$35
*
At a glance
- Drugs Nitazoxanide (Primary) ; Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 28 Apr 2013 Results presented at the 48th Annual Meeting of the European Association for the Study of the Liver.
- 01 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Jun 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.